Ribrag, V <br/><br/>
VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease.  [electronic resource] 

 -  Bone marrow transplantation  May 1998 
 - 969-74 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0268-3369 
<br/><br/><label>Standard No.: </label>10.1038/sj.bmt.1701202  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cisplatin--administration & dosage<br/>Disease-Free Survival<br/>Etoposide--administration & dosage<br/>Female<br/>Hodgkin Disease--drug therapy<br/>Humans<br/>Ifosfamide--administration & dosage<br/>Male<br/>Middle Aged<br/>Prognosis<br/>Recurrence<br/>Salvage Therapy